IDEAYA Biosciences announced that it has enrolled its first patient in the Phase 1 dose‑escalation trial of IDE574, a first‑in‑class oral dual inhibitor of lysine acetyltransferases KAT6 and KAT7. The enrollment, which took place on April 6 2026, marks the transition of the candidate from preclinical development into early human testing.
IDE574 is equipotent against KAT6 and KAT7, with single‑digit to low‑teen nanomolar cellular potency and 350‑to‑2,000‑fold selectivity over related paralogs KAT5 and KAT8. By simultaneously blocking both enzymes, the drug aims to disrupt epigenetic programs that drive tumor growth and to overcome resistance that has limited single‑target epigenetic agents. The trial will evaluate safety, efficacy and pharmacokinetics in patients with breast, prostate, colorectal and lung cancers, including hormone‑refractory breast cancer driven by ESR1 mutations.
“We are thrilled to advance another potential first‑in‑class agent into the clinic that targets large solid tumor indications of high unmet need, including breast, prostate, CRC, and lung cancer,” said CEO Yujiro S. Hata. “We believe the novel chromatin remodeling mechanism of the KAT6/7 dual inhibitor IDE574 has the potential for monotherapy efficacy and to treat breast cancer patients refractory to hormone‑based therapy due to ESR1 mutations, and to evaluate rational combinations with assets in the IDEAYA pipeline.” Chief Scientific Officer Michael White added, “Targeting mechanisms of resistance and tumor heterogeneity in cancer are core strategies of our R&D efforts, and we are excited to advance IDE574 in the clinic to evaluate its potential as a monotherapy agent to drive deeper, more durable antitumor responses for patients versus historical clinical data published with KAT6‑selective agents.”
IDEAYA’s strategy of advancing multiple first‑in‑class programs simultaneously is designed to reduce reliance on any single asset. In addition to IDE574, the company recently opened a first‑patient‑in for a combination study of IDE849 and IDE161 in March 2026 and plans to present preclinical data for IDE574 at the American Association for Cancer Research (AACR) 2026 meeting. The company’s precision‑oncology platform also includes synthetic‑lethality and antibody‑drug‑conjugate programs.
Earlier this year, IDEAYA reported Q4 2025 results that included a net loss of $83.3 million and collaboration revenue of $10.9 million. Research and development expenses for the quarter were $86.6 million, down from $140.2 million in Q4 2024, largely due to a significant upfront payment received in the prior year. The company’s cash, cash equivalents and marketable securities stood at approximately $1.05 billion as of December 31 2025, a balance that management expects will fund operations through 2029.
The first‑patient enrollment in the IDE574 trial is a concrete step toward potential regulatory submissions and eventual commercialization. By demonstrating safety and early pharmacodynamic signals, IDEAYA will be positioned to pursue larger studies and to explore partnership or licensing opportunities that could accelerate the drug’s development and broaden its impact across solid‑tumor indications.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.